Table 1:  Main characteristics of the 6 heart transplant patients with COVID-19
Patient 1  Patient 2  Patient 3  Patient 4  Patient 5  Patient 6
Demographics
 Age (years)  69  82  65  71  62  50
 Gender  Male  Male  Male  Male  Male  Female
 Time from heart transplant (years)  5  16  11  1  22  13
 Risk factors
  BMI (kg/m2)  22.4  23.6  24.5  25.3  32.6  21.5
  Arterial hypertension  −  +  +  +  +  +
  Dyslipidaemia  −  +  +  −  +  −
  Diabetes mellitus  −  −  −  −  −  −
  Former smoker  +  −  −  −  −  −
  Extracardiac arteriopathy  −  −  −  −  −  −
  COPD  −  −  −  −  −  −
  Stroke  −  −  −  −  −  −
  Malignancy  −  −  +  −  −  +
  GFR (ml/min)  80  40  71  82  48  85
  Previous PCI  −  +  −  −  −  −
  NYHA class  I  II  I  I  I  I
 Immunosuppressive therapy (mg/day)
  Cyclosporine  120  120  160  200  135  70
  Mycophenolate  1440  −  1440  1440  1440  −
  Everolimus  −  −  −  −  −  2
COVID-19 onset
 Presenting symptoms
  Cough  +  +  +  +  +  +
  Shortness of breath  +  +  +  +  +  +
  Myalgia  −  +  +  +  +  +
  Anosmia  −  −  +  +  +  +
  Headache  −  −  −  −  +  +
  Sinusitis  −  −  −  −  −  +
  Gastrointestinal symptoms  −  −  −  −  +  +
 NPS test  +  +  +  +  +  +
 X-ray pneumonia signs  +  +   +  +  −
 Fever peak (°C)  38.0  38.6  38.0  39.5  38.5  39.2
 Hospitalization  +  +  +  +  +  −
 SpO2 at admission (%)  91  85  97  78  85
 Worst SpO2 during hospitalization (%)  88  75  88  75  65
 Laboratory results at admission
  WBC count (cells per 109/l)  10.00  9.24  4.00  7.50  5.90
  Hb (g/dl)  10.0  13.5  12.0  13.7  13.5
  Platelets (cells per 109/l)  400  113  215  301  151
  Lymphocyte (cells per 109/l)  0.35  0.32  0.55  0.90  0.20
  CRP (mg/dl)  157  140  3.3  72  29
  PCT (ng/ml)  0.26   0.09  0  0
  Serum creatinine (mg/dl)  1.29  2.1  1.79  1.3  2
  Troponin I (ng/dl)  34   8  18  24
 LVEF (%)  55  45  70  55  50
Treatment and outcomes
 Hydroxychloroquine  +  +  +  +  +  −
 Lopinavir/ritonavir  +  −  −  −  +  −
 Corticosteroid therapy  +  +  +  +  +  −
 Modification of immunosuppressive therapya  +  +  +  +  +  −
  % Reduction of cyclosporine  40  100  60  50  40  0
  % Reduction of mycophenolate  75  0  0  50  50  0
 Antibiotics prophylaxis  +  +  +  +  +  +
 ICU stay  +  −  −  −  +
  ICU length of stay  18  −  −  −  2
 High flow O2  −  +  −  +  +
 NIV  −  +  −  +  +
 Intubation  +  −  −  −  −
 Complications
  Respiratory  −  ARDS  −  −  −
  Neurological  Ischaemic stroke  −  −  −  −
  Infective  Sepsis  −  −  −  −
 In-hospital length of stay  24  10  13  27  24
 Days to negative NPS testb    10  7  15  14c
 Pronation  −  −  −  +  +
 Discharged  −  −  +  +  +
 Dead  +  +  −  −  −  −
a  In-hospital percentage reduction from last follow-up dose of immunosuppressant.
b  Days from first positive NPS test to first seriate negative NPS test and clinical resolution of symptoms.
c  The patient has been asymptomatic since receiving the results of the first NPS test, which was repeated after 14 days, per government regulations.
ARDS: acute respiratory distress syndrome; BMI: body mass index; CRP: C-reactive protein; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate; Hb: haemoglobin; ICU: intensive care unit; LVEF: left ventricular ejection fraction; NIV: non-invasive ventilation; NPS: naso-pharyngeal swab test; NYHA: New York heart association; PCI: percutaneous coronary intervention; PCT: procalcitonin; SpO2: oxygen saturation; WBC: white blood cells.